Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | LGK974 |
Synonyms | |
Therapy Description |
LGK974 binds to and inhibits porcupine (PORCN), resulting in decreased secretion of Wnt ligands and concomitant decrease in Wnt signaling, potentially resulting in reduced cell growth in tumors with dysregulated Wnt signaling (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LGK974 | WNT974|WNT-974 | WNT Inhibitor 10 | LGK974 (WNT-974) binds to and inhibits porcupine (PORCN), resulting in decreased secretion of Wnt ligands and concomitant decrease in Wnt signaling, potentially resulting in reduced cell growth in tumors with dysregulated Wnt signaling (PMID: 32104684). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NOTCH1 C478F | head and neck squamous cell carcinoma | sensitive | LGK974 | Preclinical | Actionable | In a preclinical study, LGK974 inhibited growth of head and neck squamous cell carcinoma cells harboring NOTCH1 C478F in culture and xenograft models (PMID: 24277854). | 24277854 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Recruiting | USA | 2 |
NCT02649530 | Phase II | LGK974 | An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma | Withdrawn | USA | 0 |